

**Freedom of Information Act 2000**

**The Royal Cornwall Hospitals NHS Trust Response to Information request**

**Date Request Received: 231 October 2025**

**Ref:30787**

**Requested Information:**

Q1. How many patients have been treated in the **past 3 months** with the following agents for melanoma (any stage):

- Cobimetinib
- Dabrafenib
- Dabrafenib + Trametinib
- Dacarbazine
- Denosumab
- Encorafenib + Binimetinib
- Ipilimumab monotherapy
- Ipilimumab + Nivolumab
- Nivolumab monotherapy
- Nivolumab + Relatlimab
- Pembrolizumab
- Trametinib
- Vemurafenib
- Vemurafenib + Cobimetinib
- Other active systemic anti-cancer therapy
- Palliative care only

Q2. If possible, could you please provide the patients treated in the **past 3 months** with the following agents for metastatic melanoma ONLY:

- Ipilimumab monotherapy
- Ipilimumab + Nivolumab
- Nivolumab monotherapy
- Nivolumab + Relatlimab
- Pembrolizumab
- Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)
- Other active systemic anti-cancer therapy
- Palliative care only

Q3. In the **last 3 months**, how many patients have been initiated\* on the following agents for treatment for melanoma?

- Ipilimumab (monotherapy)
- Nivolumab (monotherapy)

- Nivolumab AND Ipilimumab (combination)
- Nivolumab AND Relatlimab
- Pembrolizumab
- Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)
- Other active systemic anti-cancer therapy

\*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Q4. Does your trust participate in any clinical trials for Melanoma? If so, please provide the name of each trial, and the number of patients taking part.

### Response:

**Q1.** How many patients have been treated in the **past 3 months** with the following agents for melanoma (any stage):

- Cobimetinib **0**
- Dabrafenib **0**
- Dabrafenib + Trametinib **4**
- Dacarbazine **0**
- Denosumab **1**
- Encorafenib + Binimetinib **15**
- Ipilimumab monotherapy **0**
- Ipilimumab + Nivolumab **8**
- Nivolumab monotherapy **12**
- Nivolumab + Relatlimab **21**
- Pembrolizumab **29**
- Trametinib **0**
- Vemurafenib **0**
- Vemurafenib + Cobimetinib **0**
- Other active systemic anti-cancer therapy **1**
- Palliative care only **1 first treatment start.**

**Q2.** If possible, could you please provide the patients treated in the **past 3 months** with the following agents for metastatic melanoma ONLY:

- Ipilimumab monotherapy **0**
- Ipilimumab + Nivolumab **8**
- Nivolumab monotherapy **12**
- Nivolumab + Relatlimab **21**
- Pembrolizumab **8**

- Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib) **19**
- Other active systemic anti-cancer therapy **1**
- Palliative care only **1 first treatment start**.

**Q3.** In the **last 3 months**, how many patients have been initiated\* on the following agents for treatment for melanoma?

- Ipilimumab (monotherapy) **0**
- Nivolumab (monotherapy)
- Nivolumab AND Ipilimumab (combination) **5**
- Nivolumab AND Relatlimab **3**
- Pembrolizumab **5**
- Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib) **5**
- Other active systemic anti-cancer therapy **0**

\*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

**Q4.** Does your trust participate in any clinical trials for Melanoma? If so, please provide the name of each trial, and the number of patients taking part.

| Study Short Title                                                                        | Study Full Title                                                                                                                                                                         | Active Participants |
|------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|
| DANTE (Duration of Anti-PD1 therapy for melanoma)                                        | DANTE: A randomised phase III trial to evaluate the Duration of ANti-PD1 monoclonal antibody Treatment in patients with metastatic mELanoma                                              | 2 on follow-up      |
| BNT111-01<br>_Phase II trial with BNT111 and cemiplimab<br>_Melanoma (ICON ID 4781-0020) | Open-label, randomized Phase II trial with BNT111 and cemiplimab in combination or as single agents in patients with anti-PD1-refractory/relapsed, unresectable Stage III or IV melanoma | 1 on follow-up      |
| Melanoma Wide Excision Trial – MelMarT-II                                                | A Phase III, multicentre, multinational randomised control trial investigating 1cm v 2cm wide excision margins for primary cutaneous melanoma.                                           | 26 on follow-up     |

### Additional Commentary

With reference to the clinical trial question (Q4), the data included relates to any clinical trials for the treatment of Melanoma which are currently recruiting participants or have participants under treatment or in follow-up.

The number of active participants relates to those participants currently undergoing treatment or in follow-up.

**Attachment(s):**

No Attachment(s)

**Date Response sent: 6 November 2025**